Eric Kim is currently the Director of Clinical Science at Pfizer Oncology, where they focus on the development of Sigvotatug vedotin (SGN-B6A). Previously, they served as a Principal Clinical Scientist at Seagen and Pfizer, specializing in late-stage clinical development in oncology. Eric's past experience includes roles as an Early Clinical Scientist Fellow at Merck and Adjunct Faculty at Rutgers University. They hold a Doctor of Pharmacy (PharmD), a Bachelor of Science (B.S.) in Biochemistry, and are pursuing a Master of Business Administration (MBA) in Finance at Washington State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices